166 related articles for article (PubMed ID: 7520585)
1. Quantitation of prostate-specific acid phosphatase in prostate cancer: reproducibility and correlation with subjective grade.
Zhou R; Hammond EH; Sause WT; Rubin P; Emami B; Pilepich MV; Asbell SD; Parker DL
Mod Pathol; 1994 May; 7(4):440-8. PubMed ID: 7520585
[TBL] [Abstract][Full Text] [Related]
2. Correlation of survival with quantitative tissue staining of prostate specific acid phosphatase in patients with prostate carcinoma by using microscopic image analysis: a preliminary report of correlative studies on RTOG protocols 75-06, 77-06, and 83-07.
Zhou R; Sause WT; Hammond EH; Rubin P; Perez C; Pilepich MV; Asbell SD; Parker DL
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):823-9. PubMed ID: 7591889
[TBL] [Abstract][Full Text] [Related]
3. Quantitative peroxidase-antiperoxidase complex-substrate mass determination in tissue sections by a dual wavelength method.
Zhou R; Parker DL; Hammond EH
Anal Quant Cytol Histol; 1992 Apr; 14(2):73-80. PubMed ID: 1590900
[TBL] [Abstract][Full Text] [Related]
4. [The histochemistry of complex carbohydrates in the prostatic tumor].
Sugiyama T
Hinyokika Kiyo; 1985 Jan; 31(1):49-69. PubMed ID: 2581429
[TBL] [Abstract][Full Text] [Related]
5. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
6. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
Moul JW; Connelly RR; Perahia B; McLeod DG
J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
10. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical acid phosphatase level and tumor grade in prostatic carcinoma.
Bentz MS; Cohen C; Demers LM; Budgeon LR
Arch Pathol Lab Med; 1982 Sep; 106(9):476-80. PubMed ID: 6287961
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
[TBL] [Abstract][Full Text] [Related]
13. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
16. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
Takeda H; Akakura K; Masai M; Akimoto S; Yatani R; Shimazaki J
Cancer; 1996 Mar; 77(5):934-40. PubMed ID: 8608487
[TBL] [Abstract][Full Text] [Related]
19. Grading prostate cancer.
Bostwick DG
Am J Clin Pathol; 1994 Oct; 102(4 Suppl 1):S38-56. PubMed ID: 7524306
[TBL] [Abstract][Full Text] [Related]
20. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]